chloroquine has been researched along with minocycline in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Gill, F; Miller, LH; Neva, FA | 1 |
| Carson, PE; Frischer, H; Rieckmann, KH; Willerson, D | 1 |
| Kaddu, JB; Peters, W; Warhurst, DC | 1 |
| Ferraroni, JJ | 1 |
| Dommergues, MA; Gressens, P; Plaisant, F; Verney, C | 1 |
| Kalish, RS; Koujak, S | 1 |
| Fenollar, F; Feurle, GE; Moos, V; Raoult, D; Schneider, T | 1 |
| Sahu, R; Tekwani, BL; Walker, LA | 1 |
1 review(s) available for chloroquine and minocycline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for chloroquine and minocycline
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Failure of chloroquine in human babesiosis (Babesia microti): case report and chemotherapeutic trials in hamsters.
Topics: Animals; Babesiosis; Benzamidines; Chloroquine; Cricetinae; Drug Resistance; Humans; Male; Metronidazole; Middle Aged; Minocycline; Pentamidine; Pyrimethamine; Recurrence; Sulfadiazine; Tetracycline; Time Factors | 1978 |
Effects of minocycline against chloroquine-resistant falciparum malaria.
Topics: Anopheles; Chloroquine; Drug Resistance; Erythrocytes; Humans; Malaria; Male; Minocycline; Plasmodium falciparum; Tetracycline; Vietnam | 1972 |
The chemotherapy of rodent malaria, XIX. The action of a tetracycline derivative, minocycline, on drug-resistant Plasmodium berghei.
Topics: Animals; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Malaria; Mice; Minocycline; Plasmodium berghei; Rodent Diseases; Spectrum Analysis; Tetracycline | 1974 |
[Chloroquine- and fansidar-resistant falciparum malaria treated with minocycline].
Topics: Adult; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Male; Minocycline; Plasmodium falciparum; Pyrimethamine; Sulfadoxine; Sulfanilamides; Tetracyclines | 1983 |
Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection.
Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Antirheumatic Agents; Brain; Brain Injuries; Cell Count; Cell Death; Cerebral Cortex; Cerebral Palsy; Chloroquine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Glycoproteins; Ibotenic Acid; Immunohistochemistry; Lectins; Leukemic Infiltration; Leukocyte Common Antigens; Macrophage-1 Antigen; Mice; Microglia; Minocycline; Neurons; Neuroprotective Agents; Proliferating Cell Nuclear Antigen; Staining and Labeling; Time Factors | 2003 |
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
Topics: Antigen Presentation; Cell Proliferation; Cells, Cultured; Chloroquine; Doxycycline; Humans; Minocycline; T-Lymphocytes; Tetanus Toxoid | 2004 |
The combination of chloroquine and minocycline, a therapeutic option in cerebrospinal infection of Whipple's disease refractory to treatment with ceftriaxone, meropenem and co-trimoxazole.
Topics: Anti-Bacterial Agents; Ceftriaxone; Central Nervous System Diseases; Chloroquine; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Male; Meropenem; Microbial Sensitivity Tests; Minocycline; Thienamycins; Trimethoprim, Sulfamethoxazole Drug Combination; Whipple Disease | 2012 |
In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Malaria; Male; Mice; Minocycline; Parasitemia; Parasitic Sensitivity Tests; Plasmodium berghei; Plasmodium falciparum; Tigecycline | 2014 |